Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Adjuvant anti‐VEGF therapy for overall survival and relapse‐free survival in patients with resected non‐metastatic colorectal cancer

Esta versión no es la más reciente

ver la versión actual 25 marzo 2020

Información

DOI:
https://doi.org/10.1002/14651858.CD012460Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 07 diciembre 2016see what's new
Tipo:
  1. Intervention
Etapa:
  1. Protocol
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Colorrectal

Copyright:
  1. Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • David Lok Hang Chan

    Correspondencia a: Department of Medical Oncology, Royal North Shore Hospital, St Leonards, Australia

    [email protected]

    [email protected]

  • David Espinoza

    NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia

  • Joseph Chan

    Department of Medicine, University of Sydney, St Leonards, Australia

  • Adrian Lee

    Department of Medical Oncology, Royal North Shore Hospital, St Leonards, Australia

  • Wasek Faisal

    Department of Medical Oncology, Royal North Shore Hospital, St Leonards, Australia

  • Eva Segelov

    Medical Oncology, St Vincent's Hospital, Darlinghurst, Australia

  • Nick Pavlakis

    Department of Medical Oncology, Royal North Shore Hospital, St Leonards, Australia

Contributions of authors

DC, DE, JC, AL, WF, ES and NP all contributed to writing this Cochrane protocol.

Sources of support

Internal sources

  • Nil, Other.

External sources

  • Nil, Other.

Declarations of interest

Eva Segelov has received travel grant support from Roche, Merck Serono, Amgen and Sanofi‐Aventis. She has attended advisory boards for Roche, Merck Serono and Sanofi‐Aventis.

Nick Pavlakis has received speaking honoraria and travel grant support from Roche, Amgen and Sanofi‐Aventis; he has sat on advisory boards for Roche, AlphaPharm, Amgen and Sanofi‐Aventis; and received research funding from Sanofi‐Aventis.
For the other authors, no conflicts of interest.

Acknowledgements

We acknowledge the Cochrane Colorectal Cancer Group editorial office, editors and the peer referees for their constructive comments, advice and administrative support. And Cochrane Copy Edit Support for careful reading and suggestions.

Version history

Published

Title

Stage

Authors

Version

2020 Mar 25

Adjuvant anti‐VEGF therapy for overall survival and relapse‐free survival in patients with resected non‐metastatic colorectal cancer

Protocol

David Lok Hang Chan, David Espinoza, Joseph Chan, Adrian Lee, Wasek Faisal, Eva Segelov, Nick Pavlakis

https://doi.org/10.1002/14651858.CD012460.pub2

2016 Dec 07

Adjuvant anti‐VEGF therapy for overall survival and relapse‐free survival in patients with resected non‐metastatic colorectal cancer

Protocol

David Lok Hang Chan, David Espinoza, Joseph Chan, Adrian Lee, Wasek Faisal, Eva Segelov, Nick Pavlakis

https://doi.org/10.1002/14651858.CD012460

Table 1. Frequency and five‐5 year overall survival for colorectal cancer

Stage

Frequency

Metastases

5‐ year disease‐free survival

5‐ year overall survival

Usual recommended treatment after surgery

I

39% (I and II)

No

95%

83%

Observation

II

39% (I and II)

No

85%

70%

Consider adjuvant chemotherapy

III

36%

No

69%

58%

Recommend adjuvant chemotherapy (e.g. FOLFOX)

IV

20%

Yes

(0%)

13%

Surgery not possible in most cases
Figuras y tablas -
Table 1. Frequency and five‐5 year overall survival for colorectal cancer
Ir a la tabla del protocolo